High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
NCT07223385
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death. Both pre-existing CVD and the use of androgen deprivation therapy (ADT)-a key cornerstone of treatment for men with locally advanced or metastatic PC1,2 contribute to increased CV risk.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer (Diagnosis)
- Prostate Cancer Stage IV
- CV Risk
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 45 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Cedars-Sinai Medical Center
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars Sinai Medical Center · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.